Topical Steroids for Children: Potency Guide & How to Apply
TL;DR
- Topical corticosteroids (TCS) remain the first-line anti-inflammatory treatment for childhood eczema; potency should be matched to the child's age, body site, and disease severity.
- The US classification runs from Class VII (mildest — hydrocortisone 1%) to Class I (superpotent — clobetasol propionate 0.05%). Most paediatric flares respond to Class IV–VII agents.
- Fingertip units (FTUs) provide a practical, reproducible way to measure dose and prevent both under- and over-treatment.
- Steroid phobia is common and well-documented — it leads to under-treatment more often than overuse causes harm.
- When mid-potency TCS fail or for sensitive sites (face, skin folds), calcineurin inhibitors (tacrolimus, pimecrolimus) offer a steroid-sparing alternative.
Atopic dermatitis (eczema) affects an estimated 15–20% of children worldwide and up to 13% of children in the United States, making it the most common chronic inflammatory skin condition in paediatric practice (Eichenfield et al., 2014). Topical corticosteroids have been the backbone of eczema management for over six decades, yet confusion around potency classes, application technique, and safety continues to undermine adherence. This topical steroids children guide distils current evidence — primarily from the American Academy of Dermatology (AAD) guidelines and the UK National Institute for Health and Care Excellence (NICE CG57) — into a practical framework for caregivers and clinicians.
How Topical Corticosteroids Work
Topical corticosteroids exert their therapeutic effect by binding to intracellular glucocorticoid receptors in keratinocytes, fibroblasts, and immune cells within the skin. The activated receptor complex translocates to the nucleus, where it suppresses pro-inflammatory transcription factors (notably NF-κB and AP-1), reducing the production of cytokines, prostaglandins, and leukotrienes that drive the itch-scratch cycle.
In practical terms, this means TCS accomplish three things simultaneously:
- Anti-inflammatory action — reducing redness, swelling, and heat
- Antipruritic effect — dampening itch, which breaks the scratch-damage-flare loop
- Vasoconstrictive effect — blanching the superficial vasculature, which correlates roughly with potency
The vehicle matters. Ointments are more occlusive than creams, enhancing drug penetration by 2–10-fold for the same active ingredient. This is why betamethasone valerate 0.1% in an ointment base sits in a higher potency class than the same concentration in a cream. For children, ointments are generally preferred for dry, lichenified areas, while creams may be better tolerated on weeping or intertriginous (fold) areas where occlusion could promote maceration.
Potency Classification: The Seven-Class System
The Stoughton–Cornell classification used in the United States and referenced by the AAD divides TCS into seven classes based on vasoconstrictor assay potency. Class I is the most potent; Class VII is the least. The table below lists representative agents with paediatric-use notes.
| Class | Potency | Representative Agent | Paediatric Notes |
|---|---|---|---|
| I | Superpotent | clobetasol propionate 0.05% (Temovate) | Generally avoided in children. If used, limit to ≤2 weeks on thick-skinned sites (palms, soles) under specialist supervision. Not for face or folds. |
| II | Potent | fluocinonide 0.05% (Lidex); desoximetasone 0.25% | Specialist-initiated for severe, refractory patches on trunk/extremities. Short courses only. |
| III | Upper mid-strength | betamethasone dipropionate 0.05% cream; fluticasone propionate 0.005% ointment | May be used on trunk/limbs for moderate-to-severe flares; avoid face and folds. |
| IV | Mid-strength | triamcinolone acetonide 0.1% cream; mometasone furoate 0.1% cream (Elocon) | Workhorse class for moderate paediatric eczema on trunk and extremities. Mometasone approved ≥2 years. |
| V | Lower mid-strength | fluticasone propionate 0.05% cream (Cutivate); betamethasone valerate 0.1% cream | Suitable for mild-to-moderate disease on body. Fluticasone propionate cream approved ≥3 months for atopic dermatitis. |
| VI | Mild | desonide 0.05% (DesOwen); alclometasone dipropionate 0.05% (Aclovate) | Preferred for face, neck, axillae, groin, and diaper area. Desonide approved ≥3 months. |
| VII | Least potent | hydrocortisone 1% or 2.5% | Available OTC. First-line for mild facial or fold eczema. Safe for short-to-medium courses in infants. |
Key point: NICE CG57 uses a four-tier UK system (mild → moderate → potent → very potent) rather than seven classes. When reading UK resources, "potent" roughly equates to US Classes II–III, and "moderate" maps to Classes IV–V.
Choosing the Right Potency by Body Area
The single most important principle in paediatric TCS prescribing is matching potency to site. Skin thickness varies dramatically across the body, and thinner skin absorbs more drug — increasing both efficacy and risk.
Recommended starting potency by anatomical site in children:
| Body Area | Skin Thickness | Recommended Starting Class | Examples |
|---|---|---|---|
| Eyelids | Very thin | VII only | hydrocortisone 1%; consider calcineurin inhibitor |
| Face and neck | Thin | VI–VII | hydrocortisone 1–2.5%, desonide 0.05% |
| Axillae, groin, and skin folds | Thin, occluded | VI–VII | desonide 0.05%, alclometasone 0.05% |
| Diaper area | Thin, occluded | VII (avoid potent TCS) | hydrocortisone 1%; avoid fluorinated steroids |
| Trunk (chest, abdomen, back) | Moderate | V–IV | fluticasone propionate 0.05% cream, triamcinolone 0.1% |
| Arms and legs | Moderate | V–IV | mometasone furoate 0.1%, betamethasone valerate 0.1% cream |
| Palms and soles | Thick | III–II (short course) | betamethasone dipropionate 0.05%, fluocinonide 0.05% |
| Scalp | Variable | V–IV (lotion/solution vehicle) | fluocinolone acetonide 0.01% oil, betamethasone valerate 0.1% lotion |
The AAD guidelines recommend starting with the lowest effective potency and stepping up only if there is inadequate response after 1–2 weeks of proper application (Eichenfield et al., 2014). NICE CG57 similarly advises using mild TCS for mild eczema and moderate TCS for moderate flares, reserving potent agents for severe or refractory disease under specialist guidance.
Fingertip Units: Measuring the Right Amount
One of the most practical advances in TCS dosing is the fingertip unit (FTU), introduced by Long and Finlay in 1991. One FTU is the amount of cream or ointment squeezed from a standard 5 mm nozzle along an adult's index finger from tip to the first crease — approximately 0.5 g.
Caregivers consistently under-dose TCS when given vague instructions like "apply a thin layer." The FTU system provides concrete guidance.
Approximate FTU requirements by body area and child's age:
| Body Area | 3–6 months | 1–2 years | 3–5 years | 6–10 years |
|---|---|---|---|---|
| Face and neck | 1 | 1.5 | 1.5 | 2 |
| One arm and hand | 1 | 1.5 | 2 | 2.5 |
| One leg and foot | 1.5 | 2 | 3 | 4.5 |
| Front of trunk | 1 | 2 | 3 | 3.5 |
| Back and buttocks | 1.5 | 3 | 3.5 | 5 |
Source: adapted from Long & Finlay, 1991; values are approximations and should be adjusted to the extent of affected skin.
Practical application tips:
- Frequency: Once daily is often sufficient for moderate-potency TCS. A large randomised controlled trial found no significant benefit of twice-daily over once-daily application for agents such as fluticasone propionate and mometasone furoate. NICE CG57 recommends once- or twice-daily application depending on the preparation.
- Apply to active disease only, not to uninvolved skin.
- Emollients first, TCS second — apply the emollient liberally, wait approximately 15–30 minutes, then apply the TCS to inflamed areas. Some guidelines suggest the order matters less than ensuring both are used; the key is that the emollient should not dilute the steroid layer.
- Duration: Acute flares typically require 7–14 days. If there is no improvement after 7–14 days of appropriate-potency TCS used at adequate dose, reassess the diagnosis and adherence before stepping up.
Side Effects and Monitoring
The adverse effects of TCS are dose-, potency-, duration-, and site-dependent (Hengge et al., 2006). Most clinically significant side effects occur with prolonged use of potent-to-superpotent agents on thin skin or under occlusion.
Local Side Effects
- Skin atrophy (thinning): The most common concern. Reversible in early stages if the TCS is discontinued. Risk is greatest on the face, folds, and with fluorinated compounds.
- Striae (stretch marks): Occur in areas subject to mechanical stress (groin, axillae, inner thighs). Not reversible. Avoided by limiting potent TCS use on these sites.
- Telangiectasia: Visible small blood vessels, particularly on the face. Partially reversible.
- Perioral or periocular dermatitis: Steroid-induced papulopustular eruption, especially with mid-to-high-potency agents on the face.
- Acneiform eruption and hypertrichosis: Uncommon but reported with prolonged use.
- Hypopigmentation: Temporary, more noticeable in darker skin tones. Resolves after discontinuation.
- Contact allergy: Rare but documented allergic contact dermatitis to the steroid molecule itself or to vehicle ingredients (e.g., propylene glycol).
Systemic Side Effects
Systemic absorption sufficient to cause hypothalamic-pituitary-adrenal (HPA) axis suppression is uncommon with appropriate use of mild-to-moderate TCS. Risk factors include:
- High body-surface-area-to-weight ratio in infants and young children — makes systemic absorption proportionally greater
- Use of potent or superpotent agents over large body surface areas
- Prolonged treatment (weeks to months of continuous use)
- Occlusion (including diapers, which act as occlusive dressings)
Clinically significant adrenal suppression, growth retardation, or Cushing-like features are almost exclusively reported with misuse of potent-to-superpotent agents. When used according to guidelines, mild-to-moderate TCS carry an excellent safety record in children (Hengge et al., 2006; Eichenfield et al., 2014).
Tachyphylaxis
Tachyphylaxis — the progressive loss of therapeutic response despite continued use — is frequently discussed in dermatology, though its clinical significance in TCS therapy remains debated. The mechanism may involve downregulation of glucocorticoid receptors with prolonged continuous exposure.
Practical strategies to manage or prevent tachyphylaxis:
- Intermittent or "weekend" therapy: After achieving flare control, apply TCS two consecutive days per week (e.g., weekends) to previously affected areas. This proactive approach, supported by the AAD guidelines, reduces flare frequency without continuous daily exposure.
- Treatment holidays: Alternate weeks on and off, or switch to an emollient-only regimen between flares.
- Rotational therapy: Some clinicians rotate between two TCS of similar potency but different molecular structures, though high-quality evidence for this strategy is limited.
Steroid Phobia: The Real Risk of Under-Treatment
The term "corticosteroid phobia" was formally characterised by Charman et al. in 2000, who found that 72.5% of patients or parents expressed worry about using TCS, and 24% admitted to non-adherence driven by fear of side effects (Charman et al., 2000). Subsequent studies across multiple countries have confirmed that steroid phobia is a worldwide phenomenon.
Consequences of under-treatment due to steroid phobia include:
- Persistent, uncontrolled inflammation that leads to sleep disruption, impaired quality of life, and secondary infection
- Chronic scratching that causes lichenification — thickened, leathery skin that then requires more potent TCS to control
- Increased overall lifetime steroid exposure, because repeated inadequately treated flares demand more treatment than a single properly managed episode
- Psychological burden on the child and family
How clinicians and pharmacists can address steroid phobia:
- Quantify the amount — FTUs make the dose tangible and reassure caregivers that "a thin layer" does not mean a barely visible smear.
- Explain the potency ladder — parents who understand that hydrocortisone 1% is vastly different from clobetasol 0.05% are less likely to conflate all TCS.
- Separate topical from systemic steroids — many parents confuse topical corticosteroids with oral prednisone or anabolic steroids. Clarify that systemic absorption from low-to-mid-potency topical agents is minimal.
- Frame the risk of not treating — uncontrolled eczema carries its own complications, including impetigo, eczema herpeticum, and significant psychosocial impact.
When to Step Up: Calcineurin Inhibitors and Beyond
Topical calcineurin inhibitors (TCIs) — tacrolimus ointment (Protopic) and pimecrolimus cream (Elidel) — are non-steroidal immunomodulators that inhibit T-cell activation via calcineurin blockade. They do not cause skin atrophy, striae, or telangiectasia, making them particularly valuable for sensitive anatomical sites.
Indications for TCI use in children:
- Face, eyelids, and perioral skin where even mild TCS may cause perioral dermatitis or telangiectasia with prolonged use
- Intertriginous areas (skin folds, groin, axillae) where occlusion amplifies TCS potency
- Steroid-sparing maintenance therapy after flare control with TCS
- TCS-refractory disease or cases where caregivers have documented non-adherence due to steroid phobia
| Feature | Topical Corticosteroids | Topical Calcineurin Inhibitors |
|---|---|---|
| Mechanism | Glucocorticoid receptor → NF-κB suppression | Calcineurin inhibition → T-cell suppression |
| Atrophy risk | Yes (potency- and duration-dependent) | No |
| Approved ages | Varies by agent; hydrocortisone from birth | Pimecrolimus ≥2 years; tacrolimus 0.03% ≥2 years |
| Common side effects | Atrophy, striae, telangiectasia | Application-site burning or stinging (often transient, resolves after 1–2 weeks) |
| FDA boxed warning | No | Yes (theoretical malignancy risk — based on systemic immunosuppression data; long-term registries have not confirmed increased risk with topical use) |
| Cost | Generally low (generics available) | Higher; branded products |
| Best use in children | First-line flare control, body and extremities | Sensitive sites, maintenance, steroid-sparing |
The Cochrane review by Cury Martins et al. (2015) confirmed that topical tacrolimus 0.03% is effective for moderate-to-severe atopic dermatitis in children aged ≥2 years, with application-site reactions as the main adverse event.
Other therapies beyond TCS and TCIs:
- Crisaborole (Eucrisa), a topical phosphodiesterase-4 (PDE4) inhibitor, is FDA-approved for mild-to-moderate atopic dermatitis in patients ≥3 months. It offers another non-steroidal option, though application-site pain is reported.
- Ruxolitinib cream (Opzelura), a topical JAK inhibitor, is approved for patients ≥12 years with mild-to-moderate atopic dermatitis — not currently indicated for younger children.
- Wet-wrap therapy with diluted TCS can be used for acute severe flares under specialist supervision.
Special Populations
Infants (< 1 year)
Infants have a high body-surface-area-to-weight ratio and thinner skin barrier, increasing systemic absorption. NICE CG57 recommends:
- Use mild TCS (Class VII) as first-line
- Avoid potent or very potent agents
- Be especially cautious in the diaper area, where the occlusive environment amplifies absorption
- Emollient therapy is the foundation — liberal, frequent application of fragrance-free emollients reduces flare frequency and TCS requirements
Children with Darker Skin Tones
Post-inflammatory hypopigmentation and hyperpigmentation are more visible in children with darker skin. Eczema itself often appears as hypopigmented or lichenified patches rather than classic erythema. Under-diagnosis and under-treatment are common. TCS-related hypopigmentation is typically temporary and resolves within weeks to months of discontinuation.
Children on Other Medications
Topical corticosteroids have minimal systemic drug interactions. However, concurrent use of systemic corticosteroids (e.g., for asthma exacerbation) plus extensive topical application of potent TCS can have additive effects on the HPA axis. Coordinate with the prescribing physician if the child is receiving oral, inhaled, or intranasal corticosteroids simultaneously.
Red Flags — When to Seek Urgent Medical Care
Parents and caregivers should be instructed to seek prompt medical attention if any of the following develop:
- Signs of skin infection: increased pain, warmth, swelling, weeping, crusting (honey-coloured crust suggests impetigo), or fever — secondary bacterial infection (usually Staphylococcus aureus) requires oral antibiotics, not more TCS
- Clustered painful vesicles on eczematous skin: may indicate eczema herpeticum (herpes simplex virus superinfection) — a dermatological emergency requiring urgent antiviral therapy
- Failure to respond after 2 weeks of appropriate TCS at adequate potency and dosage — reconsider the diagnosis (contact dermatitis, fungal infection, psoriasis, scabies)
- Visible skin thinning, striae, or persistent colour change at the application site — stop TCS and consult the prescriber
- Signs of systemic steroid effect: unusual weight gain, growth deceleration, or Cushingoid features — rare but warrants HPA axis assessment (morning cortisol, ACTH stimulation test)
- Widespread flare unresponsive to topical therapy — may need systemic treatment, phototherapy, or specialist referral
Frequently Asked Questions
1. Is hydrocortisone 1% cream safe for my baby's face?
Yes. Hydrocortisone 1% (Class VII) is the standard first-line TCS for mild facial eczema in infants. Apply a thin layer once or twice daily for up to 7–14 days. If the rash does not improve, consult your child's doctor rather than switching to a stronger product on your own.
2. How long can my child use topical steroids continuously?
For mild-to-moderate TCS (Classes IV–VII), most guidelines consider 2–4 weeks of daily use safe for acute flares. After flare control, switch to intermittent "proactive" therapy (e.g., twice weekly) or emollients alone. Potent agents (Classes I–III) should generally be limited to 1–2 weeks in children and only under medical supervision.
3. Can topical steroids stunt my child's growth?
Growth suppression has been reported with prolonged, high-dose systemic corticosteroids. With appropriately used topical agents of mild-to-moderate potency, clinically significant growth effects have not been consistently demonstrated. A meta-analysis context within the AAD guidelines concluded that standard-use topical therapy does not impair linear growth (Eichenfield et al., 2014).
4. What is the difference between hydrocortisone and betamethasone?
Hydrocortisone (Class VII) is approximately 15–30 times less potent than betamethasone dipropionate (Class II–III, depending on vehicle). Hydrocortisone is suitable for mild eczema and sensitive sites; betamethasone formulations are reserved for moderate-to-severe disease on the trunk and extremities and are generally not recommended for the face or folds in children.
5. Should I apply the emollient or the steroid first?
Apply the emollient first and allow it to absorb for approximately 15–30 minutes before applying the TCS. The goal is to avoid diluting the steroid while ensuring the skin barrier is supported. Some recent guidance suggests the order matters less than consistent use of both; the critical point is that both are applied regularly.
6. What is "proactive" or "weekend" therapy?
After a flare is controlled, continue applying the TCS to previously affected areas two days per week (commonly weekends) to prevent relapse. This strategy, recommended by both the AAD and NICE, reduces flare frequency and total steroid exposure over time compared with reactive-only use.
7. Are calcineurin inhibitors safer than steroids for my child?
TCIs do not cause skin atrophy, making them advantageous for the face and folds. However, they carry an FDA boxed warning regarding a theoretical malignancy risk extrapolated from systemic immunosuppression data. Long-term post-marketing surveillance has not confirmed an increased cancer risk with topical use. TCIs and TCS are complementary tools — neither is categorically "safer"; the best choice depends on the site, severity, and treatment history.
8. My pharmacist gave me a generic — is it the same strength?
Generic TCS must meet FDA bioequivalence standards for the same active ingredient, concentration, and dosage form. However, vehicle differences (inactive ingredients) can occasionally affect tolerability — for example, a cream base may contain a fragrance or preservative that a branded version does not. If your child develops new irritation with a generic, report it to the prescriber.
References
-
NICE. Atopic eczema in under 12s: diagnosis and management. Clinical guideline CG57. 2007 (updated 2023). nice.org.uk/guidance/cg57
-
Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. PMID: 24813302
-
Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. PMID: 24813298
-
Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15. PMID: 16384751
-
Long CC, Finlay AY. The finger-tip unit — a new practical measure. Clin Exp Dermatol. 1991;16(6):444–447. PMID: 1806320
-
Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931–936. PMID: 10809850
-
Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;(7):CD009864. PMID: 26151116
-
FDA. Prescribing information: Protopic (tacrolimus) ointment. 2011. accessdata.fda.gov
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with 15 years of experience spanning hospital, community, and consultative practice. He holds a Doctor of Pharmacy degree and has contributed to formulary management, medication therapy review, and patient education programmes across multiple therapeutic areas. At PillsCard.com, Dr. Ozarchuk translates peer-reviewed evidence and regulatory guidelines into accessible, accurate drug information for a global readership.
Medical Disclaimer
This article is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The content is not a substitute for professional medical judgement. Always consult a qualified healthcare provider — such as a paediatrician, dermatologist, or pharmacist — before starting, changing, or discontinuing any medication for your child. Individual treatment decisions should account for the patient's specific medical history, concurrent medications, and clinical context. PillsCard.com and the author assume no liability for actions taken based on this information.